Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

November 12, 2024

Study Completion Date

August 31, 2029

Conditions
Essential Thrombocythemia
Interventions
BIOLOGICAL

Ropeginterferon alfa-2b

Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg

DRUG

Anagrelide

Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement

Trial Locations (65)

10002

National Taiwan University Hospital, Taipei

10449

Mackay Memorial Hospital, Taipei

11101

Shin Kong Wu Ho-Su Memorial Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

11449

Tri-Service General Hospital, Taipei

11696

Taipei Municipal Wan Fang Hospital, Taipei

22060

Far Eastern Memorial Hospital, New Taipei City

30566

Daegu Catholic University Hospital, Daegu

33305

Linkou Chang Gung Memorial Hospital, Taoyuan

40447

China Medical University Hospital, Taichung

60002

Chia-Yi Christian Hospital, Chiayi City

61363

Chiayi Chang Gung Memorial Hospital, Chiayi City

63110

Washington University School of Medicine - Division of Oncology, St Louis

70403

National Cheng Kung University Hospital, Tainan City

70965

Tainan Municipal An-Nan Hospital, Tainan City

71004

Chi Mei Medical Center, Tainan City

73657

Chi-Mei Hospital - Liouying Branch, Tainan City

77030

MD Anderson Cancer Center, Houston

80756

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

81362

Kaohsiung Veterans General Hospital, Kaohsiung City

82445

E-Da Cancer Hospital, Kaohsiung City

E-Da Hospital, Kaohsiung City

83301

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

84112

University of Utah, Salt Lake City

97002

Hualien Tzu Chi Hospital, Hualien City

119074

National University Hospital, Singapore

169608

Singapore General Hospital, Singapore

300211

The Second Hospital of Tianjin Medical University, Tianjin

V6Z 1Y6

St. Paul's Hospital, Vancouver

M5G 2C1

Princess Margaret Hospital, Toronto

H3T 1E2

Jewish General Hospital, Montreal

Unknown

Peking Union Medical College Hospital, Beijing

Peking University People's Hospital, Beijing

The First Affiliated Hospital, Chongqing Medical University, Chongqing

NanFang Hospital of Southern Medical University, Guangzhou

Union Hospital Tongji Medical College Huazhong University of Science and Technolog, Wuhan

Zhongnan Hospital of Wuhan University, Wuhan

The First Affiliated Hospital of Soochow University, Suzhou

Shengjing Hospital of China Medical University, Shenyang

Shaanxi Provincial People's Hospital, Xi'an

Qilu Hospital of Shandong University, Jinan

Ruijin Hospital affiliated to Shanghai Jiao Tong University school of Medicine, Shanghai

West China Hospital, Sichuan University, Chengdu

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

Queen Mary Hospital, Hong Kong

791-0204

Ehime University Hospital, Tōon

252-0329

Kitasato University Hospital, Sagamihara

514-8507

Mie University Hospital, Tsu

889-1692

University of Miyazaki Hospital, Miyazaki

573-1191

Kansai Medical University Hospital, Hirakata

589-8511

Kindai University Hospital, Sayama

565-0871

Osaka University Hospital, Suita

410-2295

Juntendo University Shizuoka Hospital, Izunokuni

113-8431

Juntendo University Hospital, Bunkyo City

113-8603

Nippon Medical School Hospital, Bunkyo City

141-0022

NTT Medical Center Tokyo, Shinagawa City

160-0023

Tokyo Medical University Hospital, Shinjuku

409-3898

University of Yamanashi Hospital, Chūō

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

04401

SoonChunHyang University Seoul Hospital, Seoul

06351

Samsung Medical Center, Seoul

06591

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul

08308

Korea University Guro Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PharmaEssentia

INDUSTRY

NCT04285086 - Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | Biotech Hunter | Biotech Hunter